No Photo Available

Last Update

2016-10-31T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong John Kastelein?

Dr. John J.P. Kastelein

Member, Department of Vascular Medicine

University of Amsterdam

Direct Phone: +31 ** *** ****       

Email: j***@***.nl

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

University of Amsterdam

Spui 21

Amsterdam, 1012 wx

Netherlands

Find other employees at this company (8,752)

Background Information

Employment History

Collector and Senior Collector

BankBoston

Renewal Analyst

Bank of Boston

Documentation Analyst

Bank of Boston

Credit Information Analyst III

Bank of Boston

Employee Benefits Coordinator

Bank of Boston

Home Health Aide Placement Supervisor

BOSTON VISITING NURSE ASSOCIATION

Affiliations

Clinical Advisory Board Member
Mazal Plant Pharmaceuticals Inc

Member
European Atherosclerosis Society

Member
Royal Dutch Society for Medicine & Physics

Board Member
International Task Force for CHD Prevention

Member
Council for Basic Science of the American Heart Association

Number of Executive and Steering Committees
ENHANCE

Number of Executive and Steering Committees
IDEAL

Executive Board
The International Atherosclerosis Society incorporated

Number of Executive and Steering Committees
RADIANCE

Number of Executive and Steering Committees
ILLUMINATE

Number of Executive and Steering Committees
Captivate Network Inc

Number of Executive and Steering Committees
TNT

Number of Executive and Steering Committees
JUPITER

Member of the Council for Basic Science
American Heart Association Inc

Scientific Advisory Board Member
Cerenis Therapeutics SA

Medical Advisory Board Member
gemphire therapeutics inc.

Medical Advisory Board Member
Michigan Life Therapeutics LLC

Advisor
Forbion Capital Partners

Co-Founder
uniQure N.V.

Advisor
Large Pharma

Senior Medical Advisor In Lipid Metabolism Clinical Research
Synexus Limited

Scientific Advisory Board Member
CATABASIS PHARMACEUTICALS INC

Member of Scientific Advisory Board
Omthera Pharmaceuticals , Inc.

Scientific Advisory Board Member
STICARES INTERACT

Board Member
The Cleveland Clinic Foundation

Board Member
Activity

Chairman of Aegerion's European Scientific Advisory Board
Aegerion Pharmaceuticals, Inc.

Scientific Advisory Boards Member
LifeCycle Pharma Inc

Board Member
Heinrich Wieland Preize

Member of the Medical Advisory Board
AtheroNova Inc.

Member, Scientific Advisory Board
NewsRx LLC

Fellow
European Society of Cardiology

Founder
Dezima Pharma BV

Founder
Xenon Genetics Inc.

Founder
Lipid Sciences , Inc.

Founder
Amsterdam Molecular Therapeutics

Independent Board Member
Symphony Dynamo , Inc.

Education

M.D.

M.D.

Univ. of Amsterdam

medical degree

University of Amsterdam

Web References (200 Total References)


Mazal Pharm

mazalpharmaceutical.com [cached]

John J.P. Kastelein (1954) is Professor of Medicine and chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr.


Mazal Pharm

www.mazalpharmaceutical.com [cached]

John J.P. Kastelein (1954) is Professor of Medicine and chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr.


CETP as a Therapeutic Target | NLA vClinic

lipid.realcme.com [cached]

John J.P. Kastelein, MD PhD, FESC Professor of Medicine Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam

...
John J.P. Kastelein, MD PhD, FESC John J.P. Kastelein (1954) is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr.
...
Dr. Kastelein was president of the Dutch Atherosclerosis Society (DAS) until 2009 and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS) and Fellow of the European Society of Cardiology. Professor Kastelein was also one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. AMT has recently (summer 2007) enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam. The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008. Professor Kastelein's current research interests can be found in the etiology, diagnosis, prevention and treatment ofhypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published over 680 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 72. Dr. Kastelein is an investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease. Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and JUPITER (2008) are published in the New England Journal of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet. Since recently, Dr. Kastelein has developed the use of non-invasive B-mode ultrasound as well as Nuclear Magnetic Resonance (MRI) studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis. This has lead to the recognition of the AMC as a leading center for this technique which has recently been exported to a substantial number of academic sites throughout Europe. This has culminated in the set up of NICE, Network of Imaging Centers in Europe of which Dr. Kastelein is the director. Dr. Kastelein's achievements in this field are internationally recognized by numerous invited reviews on this subject. Dr. Kastelein also serves as an International Associate Editor of the European Heart Journal. He has directed 47 postdoctoral theses and currently, he heads a team of 6 internists, 6 postdoctoral fellows, 26 MD PhD students, and a large number of laboratory technicians and clinical trial / study coordinators


CETP as a Therapeutic Target | NLA vClinic

lipid.realcme.com [cached]

John J.P. Kastelein, MD PhD, FESC Professor of Medicine Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam

...
John J.P. Kastelein, MD PhD, FESC John J.P. Kastelein (1954) is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. He received his medical degree in Amsterdam in 1980 where he subsequently received specialty training in internal medicine. Then, between 1986 and 1988, he was trained in medical genetics, lipidology and molecular biology at the University of British Columbia, Vancouver under the guidance of Prof.Dr.
...
Dr. Kastelein was president of the Dutch Atherosclerosis Society (DAS) until 2009 and chairs the National Scientific Committee on Familial Hypercholesterolemia (EHC). He also is a member of the Royal Dutch Society for Medicine & Physics, the Council for Basic Science of the American Heart Association and the European Atherosclerosis Society. He also is a board member of the International Task Force for CHD Prevention and was recently appointed to the Executive Board of the International Atherosclerosis Society (IAS) and Fellow of the European Society of Cardiology. Professor Kastelein was also one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company based on the concept of gene replacement in hereditary lipoprotein disorders. AMT has recently (summer 2007) enjoyed a successful Initial Public Offering (IPO) at EuroNext in Amsterdam. The results of the first successful human gene therapy trial were widely publicized in the media and are published in ATVB in 2008. Professor Kastelein's current research interests can be found in the etiology, diagnosis, prevention and treatment ofhypertriglyceridaemia, hypercholesterolaemia and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published over 680 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 72. Dr. Kastelein is an investigator of the Bloodomics and CardioGenics consortia, two large European Union supported endavours under the Framework Programme 7, that aim to elucidate the molecular basis of atherosclerosis and premature coronary disease. Besides the scientific programmes aimed at the etiology of atherogenesis, Dr. Kastelein also serves on a number of executive and steering committees of large intervention studies, including the IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER, RADIANCE and numerous others of which TNT (2005), RADIANCE 1 (2007), ENHANCE (2008) and JUPITER (2008) are published in the New England Journal of Medicine, IDEAL (2006) in JAMA and RADIANCE 2 (2007) in Lancet. Since recently, Dr. Kastelein has developed the use of non-invasive B-mode ultrasound as well as Nuclear Magnetic Resonance (MRI) studies of the carotid arteries for the diagnosis and assessment of novel treatments for atherosclerosis. This has lead to the recognition of the AMC as a leading center for this technique which has recently been exported to a substantial number of academic sites throughout Europe. This has culminated in the set up of NICE, Network of Imaging Centers in Europe of which Dr. Kastelein is the director. Dr. Kastelein's achievements in this field are internationally recognized by numerous invited reviews on this subject. Dr. Kastelein also serves as an International Associate Editor of the European Heart Journal. He has directed 47 postdoctoral theses and currently, he heads a team of 6 internists, 6 postdoctoral fellows, 26 MD PhD students, and a large number of laboratory technicians and clinical trial / study coordinators


CERENIS - THERAPEUTICS - Steering Committee

www.cerenis.com [cached]

Dr. John Kastelein, professor of medicine, chairman of the department of vascular medicine, Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands.

Similar Profiles

Other People with this Name

Other people with the name Kastelein

Laura Kastelein
Inntel Hotels

Mike Kastelein
British Columbia

Steve Kastelein
OSF Saint Anthony Medical Center

Richard Kastelein
Blockchain Company

Jan Kastelein
Ernst & Young LLP

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory